Investors & Media

Corporate Profile

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

Investor Relations

Sara Blum Sherman
Senior Director
Investor Relations & Strategy
+1 212-271-0740

Media Relations

Raul Damas
Brunswick Group
+1 212-333-3810

to get the latest
DBV press releases

Press Releases


05/16/2018 - 7:30 am | Corporate

DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

Download PDF (346 KB)

05/14/2018 - 6:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (256 KB)

05/14/2018 - 2:30 pm | Corporate

DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week

Download PDF (356 KB)


May 8, 2018

Deutsche Bank 43rd Annual Health Care Conference